| Literature DB >> 33235493 |
Michael Richter1, Christian Rauscher2, Alexander Kluttig3, Joachim Mallwitz4, Karl-Stefan Delank5.
Abstract
PURPOSE: Interdisciplinary multimodal pain therapy (IMPT) programs for chronic back pain are effective and recommended. The patient-centered and biopsychosocial nature of IMPT is grounded in contemporary understanding that chronic pain states reflect heightened sensitization of the nervous system rather than an issue in the tissue. Teaching patients about pain is part of IMPT programs, though a clinical guideline is lacking. This study aims to answer the following question: Does the addition of an evidence-based pain neuroscience education (PNE) lecture for patients, into an IMPT program, produce superior results than the IMPT program itself? PATIENTS AND METHODS: A non-randomized, controlled intervention study was performed with 179 back pain patients indicated for IMPT. Intervention group (N=102) received a four-week IMPT program, which contained 4 one-hour sessions PNE. Control group (N=77) received the same IMPT without the additional PNE. Primary outcome was current pain after intervention. Pain knowledge, physical function, depression, anxiety, stress, quality of life and fear-avoidance were analyzed as secondary outcomes. Outcomes were defined as change of the parameter measured before and immediately after the four-week IMPT. For each outcome, linear regression models were used to estimate the raw and adjusted (sex, age and BMI) effect of additional PNE.Entities:
Keywords: chronic back pain; interdisciplinary multimodal pain therapy; neurophysiology of pain; pain management; pain neuroscience education
Year: 2020 PMID: 33235493 PMCID: PMC7678472 DOI: 10.2147/JPR.S272943
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flow of patients through the study.
Pain-Related Content of the Four-Week IMPT Program and the Additional PNE Lectures
| Week | IMPT Program (Control and Intervention Group) | Additional PNE Lecture+ (Intervention Group Only) |
|---|---|---|
| First Week | Basic information*: | Pain and overutilization of none evidence-based therapy, role of self-empowerment, epidemiology (pain is normal), changes in asymptomatic populations, nociception vs pain, acute - chronic pain, pain as protection (I), introducing George (a brave knight with back pain), avoidance/endurance behavior |
| Second Week | Basic information*: | Pain (pizza) matrix, long-term potentiation (neuron, synapse, neurotransmitters), learning and pain, stress response, bioplasticity, sensitization: peripheral/central, the hypersensitive nervous system, nociception - bottom up and top down pain modulating pathways, strategies for evidence-based chronic pain management |
| Third week | Basic information*: | Pain as protection (II), brain development and survival, chronic pain and stress, immune response, pharmacy in the head, balance of safety and danger |
| Fourth week | Basic information*: | Self-management, graded exposure and activity after the program, flair up management |
Notes: *Performed by medical pain specialist; #performed by psychologists; +performed by physiotherapists.
Sample Description
| Control Group (N = 77) | Intervention Group (N = 102) | p-values | |||||||
|---|---|---|---|---|---|---|---|---|---|
| M | Min | Max | SD | M | Min | Max | SD | ||
| Age | 46.09 | 23 | 60 | 9.88 | 46.08 | 23 | 60 | 9.52 | 0.99 |
| Current pain level | 62.88 | 20.00 | 100.00 | 17.79 | 58.31 | 20.00 | 100.00 | 17.20 | 0.09 |
| BMI | 27.41 | 18.80 | 59.50 | 6.40 | 26.92 | 18.50 | 45.00 | 5.68 | 0.59 |
| Waiting time (days) to start IMPT | 81.99 | 10.00 | 226.00 | 42.67 | 83.83 | 8.00 | 162.00 | 29.67 | 0.75 |
| N | % | N | % | ||||||
| Pain duration 6 months–1 year | 19 | 24.70 | 18 | 17.60 | 0.19 | ||||
| Pain duration 1 year–3 years | 24 | 31.20 | 25 | 24.50 | |||||
| Pain duration >3 years | 34 | 44.20 | 59 | 57.80 | |||||
| Sex female | 41 | 53.20 | 65 | 63.70 | 0.16 | ||||
| Sex male | 36 | 46.80 | 37 | 35.30 | |||||
Abbreviations: M, mean; Min, minimum; Max, maximum; SD, standard deviation.
Changes in Primary and Secondary Outcomes for Both Groups
| Control Group | Diff* (95% CI) | Intervention Group | Diff* (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | |||||||
| Score | M | SD | M | SD | M | SD | M | SD | ||
| Current pain level | 62.88 | 17.79 | 29.79 | 20.66 | −33.09 (−38.19; −27.99) | 58.31 | 17,20 | 28,75 | 22,86 | −30.03 (−35.31; −24.76) |
| NPQ-D | 5.92 | 2.03 | 8.71 | 1.73 | 2.77 (2.33; 3.20) | 5.49 | 1.94 | 9.49 | 1.30 | 3.95 (3.50; 4.40) |
| FFbH-R | 53.10 | 15.12 | 84.71 | 12.08 | 31.73 (28.02; 35.45) | 49.28 | 12.04 | 83.79 | 14.68 | 34.95 (31.57; 38.33) |
| SF12: physical component | 33.41 | 9.17 | 46.76 | 7.38 | 13.35 (11.33; 15.38) | 34.72 | 8.77 | 48.70 | 8.14 | 14.04 (12.23; 15.85) |
| SF12: mental component | 42.76 | 10.46 | 49.49 | 9.93 | 6.73 (4.44; 9.02) | 41.64 | 12.31 | 47.51 | 10.88 | 5.89 (3.47; 8.31) |
| FABQ: work | 17.26 | 9.98 | 7.96 | 7.21 | −9.30 (−11.36; −7.24) | 17.73 | 10.69 | 7.59 | 7.98 | −10.20 (−12.35; −8.05) |
| FABQ: physical activity | 12.87 | 5.51 | 3.48 | 4.04 | −9.34 (−10.58; −8.11) | 14.67 | 4.95 | 3.42 | 4.99 | −11.25 (−12.50; −10.00) |
| DASS 21: total | 18.91 | 9.29 | 10.83 | 8.67 | −7.99 (−10.19; −5.78) | 20.14 | 12.04 | 12.17 | 10.95 | −8.42 (−10.53; −6.30) |
| DASS: depression | 6.54 | 3.48 | 3.25 | 3.58 | −3.27 (−4.11; −2.42) | 7.44 | 5.23 | 4.28 | 4.80 | −3.43 (−4.50; −2.36) |
| DASS: anxiety | 3.99 | 3.49 | 2.19 | 2.64 | −1.70 (−2.44; −0.96) | 3.96 | 3.83 | 2.58 | 3.31 | −1.49 (−2.23; −0.75) |
| DASS: stress | 8.36 | 4.31 | 5.36 | 3.88 | −2.93 (−3.97; −1.89) | 8.74 | 5.09 | 5.53 | 4.43 | −3.34 (−4.22; −2.47) |
Note: *Difference between reported means.
Effect of Additional Pain Neuroscience Education on Primary and Secondary Outcomes
| Variable | n | Parameter Estimate | 95% CI | p-value | |
|---|---|---|---|---|---|
| Current pain1 | 169 | 0.11 | −6.42 | 6.65 | 0.97 |
| Current pain2 | 168 | 0.34 | −6.23 | 6.97 | 0.92 |
| NPQ-D1 | 170 | 0.85 | 0.41 | 1.29 | < 0.01 |
| NPQ-D2 | 169 | 0.78 | 0.35 | 1.20 | < 0.01 |
| FFbH-R1 | 163 | 0.54 | −3.61 | 4.69 | 0.80 |
| FFbH-R2 | 162 | −0.30 | −4.30 | 3.69 | 0.88 |
| SF12 physical component1 | 177 | 1.52 | −0.60 | 3.65 | 0.16 |
| SF12 physical component2 | 176 | 1.29 | −0.74 | 3.32 | 0.21 |
| SF12 mental component1 | 177 | −1.44 | −4.21 | 1.33 | 0.31 |
| SF12 mental component2 | 176 | −1.30 | −4.09 | 1.50 | 0.36 |
| FABQ: work1 | 177 | −0.61 | −2.70 | 1.47 | 0.56 |
| FABQ: work2 | 176 | −0.72 | −2.84 | 1.40 | 0.51 |
| FABQ: physical1 | 177 | −0.53 | −1,89 | 0.83 | 0.44 |
| FABQ: physical2 | 176 | −0.37 | −1,74 | 1.00 | 0.59 |
| DASS: total1 | 165 | 0.46 | −2.13 | 3.06 | 0.72 |
| DASS: total2 | 165 | 0.84 | −1.74 | 3.43 | 0.52 |
| DASS: depression1 | 170 | 0.50 | −0.66 | 1.67 | 0.40 |
| DASS: depression2 | 169 | 0.64 | −0.53 | 1.80 | 0.28 |
| DASS: anxiety1 | 167 | 0.31 | −0.51 | 1.13 | 0.45 |
| DASS: anxiety2 | 167 | 0.37 | −0.45 | 1.20 | 0.37 |
| DASS: stress1 | 167 | −0.11 | −1.21 | 0.99 | 0.85 |
| DASS: stress2 | 166 | 0.12 | −0.97 | 1.21 | 0.83 |
Note: 1raw model; 2adjusted model (sex, age, BMI).